Tevogen Bio (TVGN) to Release Quarterly Earnings on Wednesday

Tevogen Bio (NASDAQ:TVGN) is expected to announce its results before the market opens on Wednesday, April 1st. Analysts expect the company to announce earnings of ($0.0620) per share for the quarter.

Tevogen Bio Price Performance

Shares of TVGN stock opened at $5.22 on Wednesday. The business’s 50 day simple moving average is $12.23 and its 200 day simple moving average is $22.41. Tevogen Bio has a one year low of $4.89 and a one year high of $75.50. The stock has a market capitalization of $21.14 million, a PE ratio of -0.55 and a beta of -0.76.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on TVGN. Weiss Ratings restated a “sell (e+)” rating on shares of Tevogen Bio in a research report on Wednesday, January 21st. Wall Street Zen cut shares of Tevogen Bio to a “strong sell” rating in a research report on Saturday. Finally, D. Boral Capital downgraded shares of Tevogen Bio from a “buy” rating to a “hold” rating in a research note on Wednesday, March 4th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Reduce” and an average price target of $100.00.

Institutional Investors Weigh In On Tevogen Bio

A number of hedge funds have recently added to or reduced their stakes in the business. Deutsche Bank AG increased its holdings in Tevogen Bio by 304.1% in the fourth quarter. Deutsche Bank AG now owns 173,734 shares of the company’s stock worth $57,000 after purchasing an additional 130,738 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Tevogen Bio by 126.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 273,694 shares of the company’s stock worth $91,000 after buying an additional 152,572 shares in the last quarter. Finally, Bridgeway Capital Management LLC grew its position in shares of Tevogen Bio by 66.7% during the 3rd quarter. Bridgeway Capital Management LLC now owns 82,500 shares of the company’s stock worth $65,000 after buying an additional 33,000 shares during the period.

About Tevogen Bio

Tevogen Bio plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).

In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections.